-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network Industry Dynamics: Drug centralized volume procurement is an important breakthrough in deepening medical reform.
2019, the country has carried out three batches of a total of 112 drugs centralized belt procurement work, the average price reduction of more than 50%, the largest decline of more than 90%.
It is understood that on August 20, 2020, the third batch of national drug belt procurement in Shanghai officially opened the bid, and produced the results of the proposed election, the procurement scale of tens of billions of yuan, a total of 189 enterprises to participate in procurement activities, including 50 listed companies.
china's leading generic pharmaceutical enterprises Yangzijiang Pharmaceuticals, Shi Pharmaceutical Group, Qilu Pharmaceuticals, Shanghai Pharmaceuticals, Hengrui Pharmaceuticals, Colum Pharmaceuticals, etc. have more varieties involved.
with the opening of the third batch of national drug belt procurement, now the local also gradually began to implement.
E.e. according to the Shandong Provincial Government Executive Meeting recently considered and adopted the "Shandong Province pharmaceutical and high-value medical supplies centralized belt procurement implementation plan", Shandong Province will be in accordance with the "belt procurement, recruitment, quality priority, ensure dosage, ensure return" requirements, the implementation of drugs and high-value medical supplies centralized belt procurement, guide pharmaceutical enterprises to fair competition, and effectively reduce the burden of mass medical expenses.
Recently, Shandong Province has selected the first batch of 40 drug varieties for the national drug market, covering cardiovascular, digestive, respiratory, oncology and other clinical disciplines, is currently the national provincial procurement of a single concentrated volume of procurement of drugs in a large number of provinces.
Sichuan Medical Insurance Bureau also recently issued the Sichuan Province drug and medical supplies centralized belt procurement implementation plan (draft for comments), will normalize the provincial belt procurement, in principle, 1-2 times a year.
according to the draft opinion, Sichuan will give priority to the selection of large clinical use, higher procurement amount, clinical use mature, full market competition, strong public response to the drug as a provincial collection varieties.
specific procurement varieties catalog will be determined through the primary election, expert review, consultation with the province three steps.
"Draft for Comments" proposed to submit the primary list with Sichuan Province signed a cooperation agreement or set up a linkage mechanism, and other provinces (cities and districts) with joint procurement intention to solicit opinions, to determine the proposed volume of procurement catalog.
this will further promote the development of provincial and municipal alliances.
Province also said that the next step will be timely implementation of the third batch of national organizations centralized procurement of drugs selected results and national organizations crown stent centralized belt procurement results.
the same time, further improve the drug network policy, formulate the provincial medical insurance fund balance retention implementation advice, and encourage medical institutions to give priority to the use of the selected varieties.
of drugs is becoming an important breakthrough in deepening medical reform.
From the first batch of "4 plus 7" pilot to the second batch of 25 provinces and cities to expand the enlargement, to the recent third batch of national volume procurement gradually started, the concentration of drug procurement is forming a normal, collection range and drug varieties are also increasing, many classic commonly used drug prices have been significantly reduced, not only let patients really enjoy the benefits, but also reduce the economic burden of the whole family, so that the people have a real sense of happiness.
volume procurement expansion for patients to bring real benefits, but there are also concerns in the industry that drug prices have been reduced, the quality of drugs will be guaranteed? According to the survey data of the department, the production cost and reasonable profit of the production enterprises account for only a small part of the drug sales price.
refore, after the price of these selected drugs dropped significantly, the main squeeze is sales costs and other "water", pharmaceutical manufacturers "can still make money", the winning bid does not affect the development of enterprises.